Anika Therapeutics (ANIK) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

ANIK · Stock Price

USD 15.14+1.29 (+9.31%)

Market Cap: $200.5M

Historical price data

Market Cap: $200.5MFounded: 1993HQ: Bedford, United States

Sector Ranking#24 in Regenerative Medicine #256 in Small Molecule Drugs

Overview

Anika Therapeutics is a mission-driven company focused on redefining orthopedic care through innovative, non-opioid, hyaluronic acid-based solutions. The company has achieved a global commercial footprint with a portfolio of regenerative scaffolds and viscosupplements, strategically partnered with J&J MedTech for key U.S. sales. Its strategy centers on leveraging a deep proprietary HA technology platform to expand indications, enhance existing products, and address the large, growing market for minimally invasive musculoskeletal treatments.

Orthopedic Regenerative MedicineOsteoarthritis Pain Management

Technology Platform

Proprietary hyaluronic acid (HA) technology platform, including Hyaff® (esterified solid scaffolds) and cross-linked HA formulations, engineered for extended residence time and tailored biomechanical properties in orthopedic applications.

Funding History

3

Total raised:$80M

Debt$50MMidCap FinancialAug 15, 2020

IPOUndisclosedUndisclosedJun 15, 2004

IPO$30MUndisclosedOct 15, 1999

Opportunities

Significant growth is driven by the global aging population and demand for non-opioid pain management, positioning Cingal for ex-U.S.

market expansion.

The fast-growing regenerative medicine segment offers further upside as surgeons adopt HA-based scaffolds like Integrity and Hyalofast to improve surgical outcomes and reduce revisions.

Risk Factors

Intense competition from larger medtech firms and generic HA products creates pricing and market share pressure.

Regulatory hurdles, particularly for U.S.

approval of Cingal, and dependence on a concentrated product portfolio and key distribution partners present material commercial and operational risks.

Competitive Landscape

Anika competes in the viscosupplement market against giants like Sanofi (Synvisc) and in regenerative orthopedics against companies like Arthrex and Smith & Nephew. Its differentiation lies in its deep, proprietary HA technology, a comprehensive portfolio addressing both pain and regeneration, and strong clinical data supporting its scaffold-based healing approach.